Pfizer has completed its acquisition of NextWave Pharmaceuticals, a privately held, specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD).

Pfizer now holds exclusive North American commercialization rights to Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension, CII, the first once-daily liquid medication approved in the U.S. for the treatment of ADHD. Quillivant XR received FDA approval Sept. 27, and is expected to be available in pharmacies in the U.S. in January 2013.